Coeptis Therapeutics
Coeptis Therapeutics is a biopharmaceutical company developing innovative cell therapy platforms for patients with cancer, autoimmune, and infectious diseases. Their mission is to improve outcomes for patients with cancer through their proprietary, allogeneic cell generation platform and a pipeline of innovative cell therapies, including collaborations with research institutions and development of novel technologies such as GEAR-NK, SNAP-CAR, and stem cell expansion technologies.
Industries
Nr. of Employees
small (1-50)
Coeptis Therapeutics
105 Bradford Road, Suite 420, Wexford, PA 15090
Products
SNAP-CAR
A cell therapy platform using monoclonal antibodies conjugated to a benzyl guanine linker, recognized by custom SNAP-CAR cells, for tunable oncology or autoimmune treatment.
GEAR-NK
A modified natural killer cell-based therapeutic optimized to be co-administered with targeted antibodies for enhanced tumor killing and immune surveillance.
Cord Blood Derived HSPCs
Hematopoietic stem and progenitor cells derived from cord blood, used to generate natural killer cells without genetic modification or cellular typing.
Unmodified Immune Effector Cell Program
A platform producing natural killer cells for allogeneic therapy without standard HLA matching, currently in Phase 1 clinical trials for anti-viral treatments.
SNAP-CAR
A cell therapy platform using monoclonal antibodies conjugated to a benzyl guanine linker, recognized by custom SNAP-CAR cells, for tunable oncology or autoimmune treatment.
GEAR-NK
A modified natural killer cell-based therapeutic optimized to be co-administered with targeted antibodies for enhanced tumor killing and immune surveillance.
Cord Blood Derived HSPCs
Hematopoietic stem and progenitor cells derived from cord blood, used to generate natural killer cells without genetic modification or cellular typing.
Unmodified Immune Effector Cell Program
A platform producing natural killer cells for allogeneic therapy without standard HLA matching, currently in Phase 1 clinical trials for anti-viral treatments.
Services
End-to-end development of unmodified allogeneic NK cell products from cord blood-derived CD34+ cells, including stem cell expansion, directed differentiation, cryopreservation, and preparation for clinical testing.
Development of modular CAR effector cells that engage tumor-targeting antibody adaptors via a covalent tag to enable programmable, multi-antigen targeting and adjustable activity.
Preclinical engineering of NK cells to resist depletion by therapeutic antibodies, enabling co-administration with monoclonal antibody therapies for improved combinatorial efficacy.
Design and development of antigen-based in vitro diagnostic assays to stratify patients likely to benefit from targeted antibody therapies and combination regimens with modified cell therapies.
End-to-end development of unmodified allogeneic NK cell products from cord blood-derived CD34+ cells, including stem cell expansion, directed differentiation, cryopreservation, and preparation for clinical testing.
Development of modular CAR effector cells that engage tumor-targeting antibody adaptors via a covalent tag to enable programmable, multi-antigen targeting and adjustable activity.
Preclinical engineering of NK cells to resist depletion by therapeutic antibodies, enabling co-administration with monoclonal antibody therapies for improved combinatorial efficacy.
Design and development of antigen-based in vitro diagnostic assays to stratify patients likely to benefit from targeted antibody therapies and combination regimens with modified cell therapies.
Expertise Areas
- Allogeneic cell therapy development
- Natural killer (NK) cell immunotherapy
- Adapter-based CAR engineering
- Gene editing for therapy optimization
Key Technologies
- Allogeneic NK cell therapy
- Cord blood-derived CD34+ HSPC expansion
- Notch-mediated stem cell expansion
- Adapter-based modular CAR systems (covalent adaptor linkage)